Get the Stockscreener App
119.45
0.04%
-0.05
After Hours:
119.45
Axsome Therapeutics Inc stock is traded at $119.45, with a volume of 593.62K.
It is down -0.04% in the last 24 hours and down -9.20% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$119.50
Open:
$119.97
24h Volume:
593.62K
Relative Volume:
0.68
Market Cap:
$5.83B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-18.29
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
-4.52%
1M Performance:
-9.20%
6M Performance:
+30.19%
1Y Performance:
+72.14%
1-Day Range:
$118.73
$122.51
1-Week Range:
$116.00
$126.70
52-Week Range:
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
119.45 | 5.83B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
10 Best Performing Growth Stocks in 2025 - Insider Monkey
Axsome at Leerink Global Biopharma: Strategic Advances in 2025 By Investing.com - Investing.com UK
Axsome Drops Generics Maker Hikma From Sunosi Drug Patent Case - Bloomberg Law
Aigen Investment Management LP Purchases Shares of 4,663 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Investment Analysts’ Recent Ratings Updates for Axsome Therapeutics (AXSM) - Defense World
Lindbrook Capital LLC Lowers Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Brokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $167.36 - MarketBeat
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing - MSN
How to Take Advantage of moves in (AXSM) - Stock Traders Daily
HC Wainwright Reiterates Buy Rating for Axsome Therapeutics (NASDAQ:AXSM) - Defense World
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals - MSN
Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025 - MSN
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld Online
Axsome Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Torray Investment Partners LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given New $160.00 Price Target at Robert W. Baird - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by New York State Common Retirement Fund - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by US Bancorp DE - MarketBeat
Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright maintains Axsome stock Buy rating, $200 target By Investing.com - Investing.com Canada
Axsome Therapeutics: Strategic Developments and Market Exclusivity Drive Buy Rating - TipRanks
H.C. Wainwright maintains Axsome stock Buy rating, $200 target - Investing.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of “Buy” by Analysts - Defense World
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Axsome settles patent litigation with Hikma over Sunosi By Investing.com - Investing.com Canada
Axsome Therapeutics gets FDA support to submit sNDA for its Alzheimer’s disease agitation treatment - MSN
Axsome resolves patent dispute with Hikma - MSN
Axsome Therapeutics Resolves Sunosi Patent Case With Hikma -March 05, 2025 at 08:08 am EST - Marketscreener.com
Axsome stock gains asHikma patent feud ends (AXSM:NASDAQ) - Seeking Alpha
Axsome Settles Patent Litigation With Hikma Related To SunosiQuick Facts - Nasdaq
Axsome settles patent litigation with Hikma over Sunosi - Investing.com India
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA - The Manila Times
Axsome Wins 16+ Years of Market Exclusivity for Sunosi in Patent Settlement - StockTitan
Robert W. Baird Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - Defense World
Axsome Therapeutics (NASDAQ:AXSM) Receives Buy Rating from Needham & Company LLC - Defense World
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $190.00 - MarketBeat
Axsome Therapeutics expects to submit sNDA for AXS-05 in Q3 - TipRanks
Axsome Therapeutics Receives FDA Indication in Support of Alzheimer's Drug Submission - Marketscreener.com
Axsome Therapeutics set for 3Q sNDA submission for AXS-05 - Investing.com
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):